Digital health company Omada valued at $1.3 billion as shares jump in Nasdaq debut-February 2024-www.financetom.com

Digital health company Omada valued at $1.3 billion as shares jump in Nasdaq debut

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Digital health company Omada valued at $1.3 billion as shares jump in Nasdaq debut

Jun 6, 2025 9:12 AM

June 6 (Reuters) - Shares of Omada Health rose

21% in their Nasdaq debut on Friday, valuing the virtual chronic

care provider at $1.28 billion.

Previous page： --FDIC Acting Chair Says Agency to Ease Banks' Living-Will Mandates, Bloomberg Reports Next page： Ripple Acquires Prime Broker Hidden Road For $1.25 Billion

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--FDIC Acting Chair Says Agency to Ease Banks' Living-Will Mandates, Bloomberg Reports

Apr 8, 2025

10:45 AM EDT, 04/08/2025 (MT Newswires) -- Price: 61.92, Change: +3.07, Percent Change: +5.22 ...

Ripple Acquires Prime Broker Hidden Road For $1.25 Billion

Apr 8, 2025

Ripple, the blockchain firm behind XRP (CRYPTO: XRP), has signed an agreement to acquire prime brokerage firm Hidden Road in a deal valued at $1.25 billion. The acquisition represents Ripple's most significant move yet to expand its offerings for institutional clients, according to CEO Brad Garlinghouse. What Happened: Speaking to Fortune, Garlinghouse emphasized the importance of building a stronger foundation...

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps

Apr 8, 2025

Pacira BioSciences, Inc ( PCRX ). on Monday settled its litigations with Fresenius Kabi USA, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and eVenus Pharmaceuticals Laboratories, Inc. related to patents for Exparel (bupivacaine liposome injectable suspension). Exparel is Pacira BioSciences' ( PCRX ) non-opioid analgesic pain management and is indicated for postsurgical analgesia. As part of the settlement, the parties will file...